Novartis announced plans to invest $23 billion in building and expanding 10 facilities in the US to combat potential drug import duties from the Trump administration, creating nearly a thousand new jobs. This move will allow Novartis to produce all of its key medicines in the US, positioning it ahead of potential sector-specific tariffs on pharmaceuticals. This commitment by Novartis follows similar large investments by Johnson & Johnson and Eli Lilly in anticipation of future trade challenges.
Full Article
Track measles outbreaks, cases and vaccine rates by state across the U.S
Measles Outbreak in 2025In 2025, the U.S. has recorded over 1,000 measles cases, making it the second-most active year for the disease since the official elimination in 2000, with Texas accounting for two-thirds of these cases. "Elimination" signifies that the disease has not spread continuously for at least 12 months, and while sporadic outbreaks have occurred since 2000, current figures pale in comparison to the 27,000 cases in 1990 and 450,000 in 1964. The introduction...
Read more